Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00719693 · ClinicalTrials.gov registry record · Phase 1
Assessment of the Effect of Food on ABT-143 Bioavailability
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 115
- Enrollment target
NCT00719693 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 115 participants.
The verdict
NCT00719693, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 115 participants
- Enrollment target
Study Summary
Single-dose, open-label, two-period crossover study of ABT-143
Interventions
- DRUG ABT-143 ( rosuvastatin calcium and fenofibric acid )
- DRUG ABT-143 (rosuvastatin calcium and fenofibric acid )
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2008-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00719693
The ClinicalTrials.gov registry entry for NCT00719693 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 115 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ABT-143 ( rosuvastatin calcium and fenofibric acid ) is the first listed.
NCT00719693 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00719693 about?
NCT00719693 is a clinical study titled "Assessment of the Effect of Food on ABT-143 Bioavailability". Single-dose, open-label, two-period crossover study of ABT-143
What is the current status of trial NCT00719693?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 115 participants. The study started on 2008-07.
What interventions are being tested in trial NCT00719693?
The interventions under investigation include: ABT-143 ( rosuvastatin calcium and fenofibric acid ) (DRUG), ABT-143 (rosuvastatin calcium and fenofibric acid ) (DRUG).
Who is sponsoring clinical trial NCT00719693?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.